Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.
You may also be interested in...
Archemix Outlicenses Aptamers To Ophthotech
Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.
Genentech’s Lucentis Ships June 30 Following Approval
Ranibizumab, for the treatment of wet age-related macular degeneration, will be priced at a substantial premium to Pfizer/OSI's Macugen.
Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.